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Abstract: The first successful use of nanoparticles (NPs) for vaccination was reported
almost 40 years ago with a virus-like particle-based vaccine against Hepatitis B. Since then, the term
NP has been expanded to accommodate a large number of novel nano-sized particles engineered
from a range of materials. The great interest in NPs is likely not only a result of the two successful
vaccines against hepatitis B and Human Papilloma Virus (HPV) that use this technology, but also due
to the versatility of those small-sized particles, as indicated by the wide range of applications reported
so far, ranging from medicinal and cosmetics to purely technical applications. In this review, we will
focus on the use of NPs, especially virus-like particles (VLPs), in the field of vaccines and will discuss
their employment as vaccines, antigen display platforms, adjuvants and drug delivery systems.
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1. Introduction
In the 18th century the English doctor Edward Jenner laid the foundation for a successful
vaccination program against smallpox. Despite the rapid advancement in vaccine development since
then, several drawbacks have been associated with these classical vaccines based on live, attenuated
or chemically inactivated viruses. For attenuated vaccines, the most common adverse effects are the
reactivation of the virulent state and severe side effects in subjects with weakened immune systems.
Chemically inactivated vaccines are considered safer and easier to handle than attenuated vaccines,
as they cannot regain their virulence. However, such vaccines stimulate a weaker immune response in
general [1].
In the 1970s, scientists with safety concerns in mind started to harness the possibility of using
subunit vaccines. Subunit vaccines consist of one or several specific proteins, which are either
responsible for inducing neutralizing antibodies (e.g., hemagglutinin of influenza virus) or are causing
disease themselves, such as for toxins (e.g., tetanus toxin). This type of vaccine has a similar safety
profile when compared to inactivated pathogens, but, likewise, it does not induce life-long immunity
and has low immunogenicity. The use of NPs provides an outstanding solution for this long-standing
problem of safety versus immunogenicity, as nanoparticles (NPs)-based vaccines have shown, so far,
the capacity to generate safer vaccines with an excellent immunological profile by giving recombinant
subunit vaccines a viral finger-print [2–4]
NPs constitute a heterogeneous category of carriers that have in common their size, ranging from
1–1000 nm. NPs used in vaccines include virus-like particles (VLPs), viral vectors, lipid nanoparticles
(LNPs), liposomes and cationic polymers [5], to name a few. The various classes of NPs used in other
technical fields are extensively reviewed elsewhere [4,6]. Most used NPs for vaccines are derived from
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viral proteins, exhibit highly repetitive structures and form VLPs; other NPs, even if not derived from
viruses, share some features such as size and repetitiveness.
Since the dawn of nanoparticle applications in vaccinology with the Hepatitis B vaccine, NPs have
become an attractive display platform for antigens and for the delivery of adjuvants. The simplicity
of production processes for nanoparticles and their high immunogenicity are major driving forces
for using such a platform. The immunogenicity is largely due to the repetitiveness and polyvalence
of the surfaces, which are a potent geometric pathogen-associated structural pattern (PASP) [7,8]
capable of inducing a strong humoral response against the displayed antigen [9]. NPs in general can
be assembled in vitro to encapsulate a variety of substances, which makes them a valuable tool to
cargo immunomodulatory sequences such as siRNA, adjuvants such as immunostimulatory sequences
(ISS) [5], and drugs such as antibiotics [5,10]. Thus, NPs can simultaneously display antigens of choice
and package adjuvants as cargo, which further increases the possibilities to tailor the conditions and
characteristics of the vaccine by modulating the immune response raised by such particles.
The size of NPs is arguably one of the most important features of their immunogenicity. Efficient
draining of antigens from the periphery to the lymph nodes allows the simultaneous delivery of both
NPs and their cargo to relevant populations of immune cells and their intracellular compartments
which initiate the adaptive immune response. Nano-sized particles have been shown to freely drain
to lymph nodes [11] and preferentially be taken up by lymph node–resident dendritic cells and
macrophages [8,12], the two main antigen-presenting cells (APCs).
The inherent versatility of NPs for antigen display and packaging of immune-stimulatory
substances allows their broad application in a large number of indications, going far beyond
use as prophylactic vaccines against infectious diseases. Indeed, VLP-based strategies for active
immunization against chronic diseases such as hypertension [13], nicotine addiction [14], arthritis [15]
and Alzheimer′s disease [16,17] have been clinically assessed. An important feature of VLPs for
these indications is their ability to overcome B cell tolerance to allow the induction of self-specific
antibodies, targeting endogenous molecules such as angiotensin II for hypertension [13] or IL-1 for
type II diabetes [18]. More details on NP-based vaccines in clinical trials are reviewed elsewhere [2].
In the following sections, we will cover the landscape of available NPs, the immunology behind
nanoparticles, focusing on NPs used for vaccination programs, popular applications of NPs and recent
developments in the field.
2. Categories of Nanoparticles
The range of NPs available for vaccination has expanded dramatically over the past 30 years [4].
Among the most popular NPs, at least seven broad categories can be identified. All of them share the
repetitive structure, a size in the nanometer range, permissibility to functionalization of the surface and
an adjuvant effect for vaccines. They differ, however, remarkably in size within the given nanometer
range, the nature of their building blocks, the mode of antigen presentation—packaged within the
NP, chemically fused to the surface, or genetically fused to the VLP—the modulatory outcome to
the immune response and, finally, their potency as immunogens. The different types of NPs are
summarized in Table 1.
Most of the NPs are built from organic, biological sources. One reason for this is likely the
continuing concerns of toxicity due to persistence in the host of non-biodegradable NPs, such as
gold [19] and carbon NPs [20]. Although inorganic NPs do hold advantages, such as consistent and
controllable methods of synthesis and rigidity of structure, adverse events, sometimes of a serious
nature, may be associated with these NPs. The nanometer size of any NPs allows access to usually
protected compartments, such as the lower lungs. In these locations, inorganic NPs which are not
easily degradable can cause persistent inflammation and ultimately fibrosis [21]. It is well appreciated,
however, that the toxicity of NPs is not an exclusive feature of inorganic NPs, as long-term persistence
is not the sole cause of toxic side effects, but also size-dependent bio-distribution through the system,
the target cells, the charge of the surface and the hydrophobicity of such particles [22].
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Table 1. General classes of nanoparticles (NPs).
Particle Characteristics and Mechanisms Size Commercial Name Ref.
Emulsions Oil in water emulsions composed of a solvent and a surfactant. Vaccine adjuvant,leads to recruitment of immune cells and induction of Th1 response. 50–600 nm
MF59™,
Montanide™ [23,24]
Inorganic NPs Rigid structure and controlable synthesis. Non-biodegradable. 0.8–200 nm AuNPs (Gold),Fulleren [21]
ISCOM Immune-stimulating complex.“Cage-like” particles.Popular ISCOMs are made of saponin, cholesterol and phospholipds. 40 nm
ISCOM,
ISCOMATRIX [25]
Lipid-based NPs Biodegradable lipidic NPs such as liposomes, micelles andsolid lipids nanoparticle. Encapsulation of antigens with controlled release. 200–1000 DOTAP [5,26]
Polymeric NPs Synthetic polymers. Allows controled release of antigens or drugs. Biodegradable. Variable PLG, PEG,polystyrene [27–29]
Carbohydrates Natural polysaccharide. Shape and size are easilymanipulated with impact on the profile of the immune response. Biodegradable. Variable
Pullulan, Advaxa™
(Inulin) [30–33]
Self-assembled proteins Self-assemblying proteins that fold into complex quartenary structure. 10–40 nm Ferritin, MVP. [34]
Viral Vectors Efficient gene transfer for transiente of stable expression. Induce robust CTL responses. Goodsafety and tolerability profile from clinical trials in humans. Variable MVA, Adeno [35]
VLPs Self-assembled viral capsides devoided of infectiousnucleic acid. Confers viral fingerprint to displayed antigens. 15–50 nm Gardasil, Cervarix. [36,37]
VLPs: Virus-Like Particles; CTL: Cytotoxic T Lymphocytes; NPs: Nanoparticles; ISCOMs: Immune-stimulating complex; Th1: T helper 1.
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Organic NPs, on the other hand, such as emulsions, immune-stimulating complexes (ISCOM),
liposomes (Figure 1A) and protein-based NPs, can be better tolerated in general, as they are easily
degraded. Emulsions are composed of a surfactant and a solvent, and have been used successfully as
adjuvants in humans with acceptable safety profiles as seen with AS01 and AS03 from GlaxoSmithKline
(GSK) in vaccines against malaria [23] and H1N1 [24], respectively. ISCOMs are immune-stimulating
complexes formed by an antigen entrapped by lipids with immunogenic characteristics such as
Quil A [25].
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Organic polymeric NPs are divided into synthetic and naturally occurring polymers. Examples 
of the former are polystyrene, and PLGA (DL-Lactic co-glycolic acid), which were reported to be 
efficacious in delivering and promoting controlled release of growth hormone in monkeys as well as 
exhibiting adjuvant functions [27]. Examples of naturally occurring polymers forming NPs are 
pullulan (CHP) [30] as well as nanogels derived from chitosan, both of which have been reported to 
be highly potent as adjuvants [31]. Chitosan has been used in humans as an excipient in a number of 
formulations and has shown good tolerability and low toxicity [32]. 
For self-assembling proteins of bacterial origin, the most important representative is ferritin 
(Figure 1D). The disadvantages of this system are the low valency of ferritin—with 24 subunits 
compared to other NPs such as VLPs with 180 subunits—and its small size (<10 nm), which are 
thought to render the particle less immunogenic; however, relevant pre-clinical results are being 
reported using such a platform with an excellent immunogenic profile. Studies to develop a vaccine 
against Influenza H1N1 were reported to be successful [33] and, more recently, the development the 
Epstein-Barr virus vaccine was reported with strong pre-clinical data [34]. 
At the moment, VLPs remain as the sole class of NP currently approved for use in humans as 
vaccines. This is most likely a consequence of the long host-pathogen co-evolution of vertebrates and 
viruses. The immune system has evolved over time to recognize conserved patterns of viruses that 
are also present in VLPs, viral vectors and some NPs, inducing a strong protective immune response. 
However, the range of NPs available and the fast pace of development will likely raise other classes 
of NPs to a similar status. 
3. NPs Successfully Used as Vaccines 
The first NP-based vaccine licensed for humans dates back to 1981, a VLP-based vaccine against 
hepatitis B virus (HBV) [38]. The recombinant HBV vaccine became feasible once researchers found 
sub-viral particles of HBV in the sera of infected subjects. The particles of sub-viral size are spherical 
assemblies of the HBV surface antigen (HBsAg) with a size of 22 nm; however, the structures are 
devoid of nucleic acid, and therefore non-infectious [36]. This discovery led to the development of 
the HBsAg derived from the plasma of infected carriers. Safety concerns regarding the use of  
human-derived products encouraged the development of second-generation VLPs, produced by 
recombinant engineering [39,40]. Two decades later, two other VLP-based vaccines were approved 
for use in humans, targeting human papilloma virus (HPV) with the trade name Cervarix®  and 
Gardasil®  (Figure 1B), which are hopefully reducing HPV-induced cancers by 50% [41]. In 2011, a 
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for use in humans, targeting human papilloma virus (HPV) with the trade name Cervarix® and
Gardasil® (Figure 1B), which are hopefully reducing HPV-induced cancers by 50% [41]. In 2011,
a fourth VLP-based vaccine was licensed for use in humans in China, a vaccine against hepatitis E.
China remains the sole country so far in which the vaccine has been licensed [37].
A fifth VLP-based vaccine against malaria was recently approved for use in humans.
The RTS,S/AS01 with the trade name of MosquirixTM, developed by GSK, is a mosaic particle based
on the hepatitis B surface antigen (HBsAg) fused to a large part of the P. falciparum circumsporozoite
antigen (CSP). The vaccine was approved with acceptable profiles of safety and tolerability.
The reported efficacy rate was as high as 50% in young children in the endemic area of sub-Saharan
Africa, leaving, however, room for improvement [23]. The timeline of development of NP-based
vaccines is represented on Figure 2.
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4. Immunology of NPs
The immune response against NPs is known to elicit both arms of the immune system, innate and
adaptive. The following sections will cover the general immune response elicited by those particles
and the strategies employed by researchers to manipulate and improve the immune response.
4.1. Fluid Phase Pattern Recognition Molecules
The innate immune system has an important defense line composed of biochemical molecules
such as the complement system molecules [42] and pentraxins [43], which circulate through the blood
stream in inactive form. Under favorable conditions, these molecules become activated and provide
important danger signals to the immune system.
The repetitiveness of viruses and, likewise, NPs promotes the deposition and fixation of the
components of the complement cascade and other multimeric proteins. This is a result of the constant
but slow deposition of C3b of the classical pathway in foreign surfaces that occurs spontaneously [42].
The repetitive surface of NPs, once covered by C3b, enhances the activity of the C3bBb convertase,
amplifying the cascade of the reactions part of the complement [44]. Other factors such as charge,
size and the nature of the building blocks of each NP are reported to interact and skew complement
activation in a NP-specific manner [28,45]. The activation of the complement system augments
the opsonization of antigens, reduces the signaling threshold needed to activate the B cell receptor
(BCR) [42], provides co-stimulation to B cells by C3 degradation products and promotes antigen
trapping in the germinal center, which contributes to the generation of memory B and long-lived
plasma cells [29]. In addition to the activation of B cells, the deposition of complement releases a potent
anaphylatoxin C3a and the chemoattractant C5a, which promotes the influx of immune cells to the site
and the activation of APCs, boosting the antibody response and overall immune response [46].
The surface of NPs can also be chemically manipulated to improve activation of complement;
this approach has been used in an experimental murine model to harness the activation of
complement for vaccination purposes. Specifically, poly-hydroxylated NPs such as pluronic-stabilized
Vaccines 2017, 5, 6 6 of 15
polypropylene sulfide (PPS) were shown to spontaneously activate complement by improving the
deposition and fixation of the C3b component of the alternative pathway [47]. Such NPs were shown to
strongly activate and induce maturation of dendritic cells (DCs) when compared to non-hydroxylated
polystyrene nanospheres [47]. Others have also reported the differential deposition of complement
components on polyethylene glycol-based (PEG) NPs with variable density of PEG and size. Ultimately,
the varying degrees of complement deposition and activation impacted the macrophage uptake of the
NPs [28].
On the other side of the spectrum, the complement system has been reported as dampening the
in vivo effects of liposomes. The deposition of components of the complement system leads to rapid
clearance without further immune activation [26].
This branch of the innate immune system has not received much attention as a target of adjuvants
and, although poorly explored, the contribution to the immune response against NPs is well established,
as viruses and NPs spontaneously activate complement that influences B and T cell responses [42,45,48].
Further studies are necessary to demonstrate the feasibility of modulating and increasingly engaging
those molecules for improved vaccination strategies.
4.2. Size and Bio-Distribution
The small size of VLPs is an important characteristic and may be viewed as a pathogen-associated
structural pattern (PASP). Pathogenic agents such as viruses and bacteria have size distributions of
10 nm to 3 µm [7], while there is almost no self-protein in the fluid of vertebrates that falls within the
same size range. Viruses have their size and complexity restricted by the size of their genomes and
the small number of proteins that they are capable of encoding [49]. Moreover, the structure of the
lymph vessels excludes complexes larger than 500 nm from freely entering the lymphatic system and
lymph nodes [47]. This favors the entry of pathogens into lymph nodes, which is where the adaptive
immune response is initiated, and it is an important mechanism for directing viral-size pathogens
towards lymph nodes where innate cells specialized in dealing with such particles reside. Within
lymphoid organs, small particles are not only transported to B cell follicles [50] but also preferentially
taken up by DCs and macrophages, but not other cell types [51,52], focusing antigen uptake on the
most important cells for the induction of protective immune responses.
Another important biophysical property of particles is charge. Nano-emulsions have been
reported to increase the infectivity of phages in vitro due to size distribution and zeta potential,
with possible implications for bacterial control in a S. aureus infection model [35]. Pre-clinical
studies have also demonstrated that by altering the charge in lipid-based particles, the profile of
bio-distribution in the tissue and the kinetics of these particles are changed [12]. This is likely a result
of charge-dependent interactions with proteins in the serum and the complement deposition that
influence the clearance of foreigner particles in vivo [53]. Of note, it is important to consider that
when changing the charge, the compositions of lipids are altered, and this could also contribute to the
effects observed.
Although size and charge as a PASP and a potent immunogen is a consensus, conflicting reports
on the impact of size on the immune response add difficulties to setting an optimal and narrow range of
size and charges. This is likely a result of additional immunogenic features of the NPs not controlled in
the experiment. This problem and other confounding factors are extensively reviewed elsewhere [54].
4.3. DCs and Macrophages
DCs and macrophages are the main APCs, and, hence, targeting these cells enhances and focuses
antigen presentation driving strong T cell responses. APCs are not only responsible for presenting
the antigens to the relevant lymphocytes, in particular T cells, but they also influence the quality
of the T cell responses induced through the composition and levels of cytokines and stimulatory
signals generated. Furthermore, engaging T cell receptors (TCRs) of T cells without secondary signals
from APCs may trigger tolerogenic pathways, leading to the abrogation of cellular responses [55].
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Thus, targeting APCs and modulating their activity represents possibly the most efficacious strategy of
inducing cellular responses of a desired nature.
Once APCs, especially DCs, uptake and process the NPs, they go through maturation and reach
an activated state (Figure 3). Once activated, these cells are able to present antigens to T cells and
initiate the adaptive immune response. It has been shown that DCs are able to present VLP-bound
antigens both through the classical major histocompatibility complex II (MHC) pathway and also
cross-present to charge MHC I molecules. This leads to both Thelper (Th) and CD8+ T cell responses
even in the absence of infection [56].
Vaccines 2017, 5, 6  7 of 15 
targeting APCs and modulating their activity represents possibly the most efficacious strategy of 
inducing cellular responses of a desired nature. 
Once APCs, especially DCs, uptake and process the NPs, they go through maturation and reach 
an activated state (Figure 3). Once activated, these cells are able to present antigens to T cells and 
initiate the adaptive immune response. It has been shown that DCs are able to present VLP-bound 
antigens both through the classical major histocompatibility complex II (MHC) pathway and also 
cross-present to charge MHC I molecules. This leads to both Thelper (Th) and CD8+ T cell responses 
even in the absence of infection [56]. 
 
Figure 3. Interaction of NPs and relevant immune cells. APCs such as dendritic cells are the main cells 
recognizing and driving the immune response against NPs. The unspecific uptake guarantees that 
those cells will internalize and process most of the pathogens and molecules. The uptake of NPs 
triggers maturation of DCs and secretion of relevant cytokines that will stimulate other cells, such as 
T cells, and modulate the immune response. Humoral immune response is favored by the repetitive 
surface which promotes BCR crosslinking and activation of B cells, leading to activation and 
production of long-lived antibodies. Cellular and cytotoxic responses are driven by the APCs that 
internalized the NPs and cross-present the antigens to T cells. 
An additional important feature of NPs is that they can transport adjuvants as cargo for delivery 
to endosomal compartments of APCs, engaging important pattern recognition receptors (PRRs), such 
as TLRs that skew and trigger stronger immune responses. Many VLPs and all viral vectors naturally 
encapsulate nucleic acid inside a protein shell, and other NPs can easily be assembled around the ISS 
and promote a similar adjuvant effect [6,32,57]. For VLPs, the nucleic acid is non-infectious, but is 
usually necessary for virus assembly and appropriate folding; however, the NA can be removed 
and/or replaced for downstream applications [58]. Generally, the foreign nucleic acid packaged in 
NPs is released within endosomal compartments of APCs after particle uptake and protein 
degradation, activating TLR3 in the presence of dsRNA, TLR7/8 with ssRNA [59] and TLR9 with non-
methylated DNA rich in CG areas, the CpG islands [60]. The activation of those pathways leads to 
the production of Th1-associated cytokines such as IFNα, TNFα and IL-1β by DCs and CCL5 and 
TNFα by macrophages in a TLR9-dependent manner [61]. It also activate interferon-stimulated genes 
(ISG) related to antiviral control as well as the production of the key cytokine IL-12 [62]. Other 
cytosolic sensors such as RIG-I and STING have been implicated in the response against VLPs in a 
few studies. One study showed STING activation by membrane disturbance caused by the entry of 
viral vectors, VLPs and liposomes [63]. The use of 5′-triphosphate–containing RNA, a RIG-I agonist, 
combined with an influenza-derived VLP was capable of increasing antibody titers and protecting 
mice against a lethal challenge with H5N1 [64]. Another study suggested an involvement of 
endogenous retrovirus-derived nucleic acids that would activate RIG-I and cGAS [65] upon VLP 
recognition by B cells. 
Figure 3. Interaction of NPs and relevant immune cells. APCs such as dendritic cells are the main
cells recognizing and driving the immune response against NPs. The unspecific uptake guarantees
that those cells will internalize and process most of the pathogens and molecules. The uptake of NPs
triggers maturation of DCs and secretion of relevant cytokines that will stimulate other cells, such as
T cells, and modulate the immune response. Humoral immune response is favored by the repetitive
surface which promotes BCR crosslinking and activation of B cells, leading to activation and production
of long-lived antibodies. Cellular and cytotoxic responses are driven by the APCs that internalized the
NPs and cross-present the antigens to T cells.
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The aforementioned immunomodulatory properties of NPs have been used for improving vaccine
formulation and nucleic acids, and other TLR ligands have been employed as adjuvants in order
to harness the anti-viral defenses of the body [66]. CpG is one of the most extensively studied TLR
ligands used as an adjuvant in pre-clinical models. Several papers have shown CpG as a strong inducer
of protective T cell responses in different disease models, such as lymphocytic choriomeningitis
virus (LCMV) and cancer [67–70]. Another example of the usage of TLR ligands is the TLR4 ligand
monophosphoryl lipid A (MPLTM), used as an adjuvant in the commercial Cervarix vaccine against
HPV [71]. MPLTM is a chemically modified derivative of lipopolysaccharide (LPS) and has been shown
to induce a stronger and prolonged response when compared to the VLP alone. A RNA-lipoplex
(RNA-LPX) system was also used as an adjuvant in cancer models and a phase I dose-escalation trial
in melanoma patients is showing promising results for patient-specific vaccines [12].
4.4. B Cell Responses
NPs are usually made up of repetitive subunits. T = 3 icosahedral VLPs, for example, are built of
180 copies of a single protein in quasi-equivalent conformations [72]. Evolution of the host-pathogen
interaction rendered B cells highly responsive to such particles. Repetitive surfaces with antigenic
determinants with a density of 12–16 and that are closely spaced—the optimal range being considered
10 nm—[73] promote crosslinking of the BCR, which constitutes an activation signal for B cells and
eliminates the need for T cell help (Figure 3). As discussed earlier, the deposition of complement on
the surface increases the interaction of VLPs and follicular dendritic cells, driving the germinal center
reaction. In addition, complement degradation products on NPs engage CD21 on B cells, enhancing B
cell activation as well as the induction of long-lived plasma cells and class switching.
It has been shown that TLR ligands packaged inside NPs such as VLPs or liposomes greatly
improve IgG responses against the model antigen TCR when compared to soluble CpG mixed with
the antigen. An interesting finding of this paper relates to the synergic role of DCs and B cells. Using
tissue-specific MyD88 knockouts, the impact of linking versus mixing antigens with TLR ligands was
compared for VLPs and soluble OVA. For soluble protein, TLR recognition and signaling on DCs was
more important for antibody responses when compared to TLR signaling in B cells. This observation
was explained by the activation of T helper cells by activated DCs, providing the signals necessary to
activate B cells. In contrast, for VLPs packaging CpG and presenting antigens, the TLR signaling in
DCs and subsequent T cell-mediated help seemed no longer necessary, as TLR-signaling on B cells
were more important for the response [74,75].
The importance of TLR ligands present in NPs for antibody responses largely depends on
the nature of the antigen and the interplay with BCR activation [76]. It was reported that highly
repetitive antigens are able to induce high IgG titers even in the absence of MyD88 in response to
TLR stimulation [77]. However, in other models where the antigen provides weaker BCR ligation, the
absence of the TLR ligand resulted in a 30-fold reduction in IgG titers [74]. Regarding the quality of
the antibody response, it is well established that TLR ligands impact isotype switching. Activation
of TLR9 in B cells is shown to favor the production of IgG2a in mice and IgG1 in humans over other
subtypes in a T-bet–dependent manner [77,78].
Another important aspect of the use of VLPs with packaged TLR7/8 and TLR9 ligands is the
increased induction of antigen-specific germinal centers (GC), which boosts the levels, affinity and
isotype switching of antibodies. A 10-fold increase in the formation of antigen-specific GC has been
reported upon immunization with antigens coupled to a TLR ligand compared to free antigen [74].
4.5. T Cell Responses
To date, most of the vaccines produced and licensed for use in humans confer protection through
the induction of antibodies. This approach has proven successful in many cases; however, it has
consistently failed in many diseases that represent a great burden to public health systems such as
malaria and HIV. It is likely that for such diseases, humoral responses alone are not enough to confer
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protection, and it is necessary to engage other arms of the immune system such as T cells. Great efforts
have therefore been made towards the development of adjuvants focusing on DC and T cell activation
(Figure 3).
Although NPs are mostly known as good inducers of antibody responses, they also hold desirable
characteristics that can be explored to induce a cellular response. As discussed above, NPs have the
right size to freely drain to lymph nodes from peripheral areas to encounter lymph node–resident
APCs. As only lymph node–resident CD8+ DCs can cross-present antigen, their adjusted size can be
used to induce cytotoxic T cell responses even in the absence of infection [79]. In addition, NPs are also
taken up by skin- or muscle-resident DCs, which causes DC maturation, leading to the upregulation
of the chemokine receptor CCR7, a homing receptor that causes DCs to migrate to lymph nodes [80],
where they arrive as fully mature DCs charged for T cell priming. Hence, NPs are presented to T cells
in an orchestrated way by a large number of different professional APCs, which increases the chance
of robust T cell activation. The ability of NPs to package RNA or DNA is a key feature in this context,
as this leads to concomitant activation of peptide-presenting DCs, further driving T cell responses.
Using VLPs, it has been shown that CpGs augment the induction of antigen-specific CD8+ T
cells when compared to the same VLP containing RNA or no TLR ligand [10], and most importantly,
they are able to reduce the toxic effects of CpG in murine models [68]. The increased expansion of
specific CD8+ T cells was correlated with anti-viral protection in the same study. There have also been
a number of studies using CpG-loaded VLPs for induction of melanoma-specific T cell responses in
humans. A combination with Imiquimod, a ligand for TLR7, was particularly effective [81,82].
For influenza vaccines, the induction of T cells responses holds promise for the production of
a universal influenza vaccine. Although antibody-based vaccines are protective, they usually are
serotype specific. A recent study demonstrated that, utilizing regimens favoring T cell response, it was
possible to protect in a mouse-adapted influenza model against homosubtypic and heterosubtypic
influenza, as the T cell response generated target conserved epitopes among those strains [83,84].
Another approach to improve T cell responses would also include adjusting vaccine schedules.
It has been shown that using escalating doses that reach a peak, followed by a decrease, is more
efficient in inducing T cell responses when compared to a schedule with a fixed dosage [85].
In the opposite trend, NPs are being modified to shut down cytotoxic T cells instead.
This approach aims to induce immune-tolerance by activating Tregs against specific auto antigens
involved with auto-immune diseases, for example. A well-described target is the aryl hydrocarbon
receptor present in DCs [86], a ligand-activated transcription factor that leads to tolerogenic responses
via FoxP3+ T cells. Along the same lines, nanoparticles of poly(lactide-co-glycolide) bearing an antigen
related to encephalomyelitis were able to ameliorate the disease by inducing antigen-specific Tregs
and leading to an anergic response. This was achieved by directing the uptake of the nanoparticle to a
specific population of macrophages bearing the scavenger receptor MARCO [87].
Whether the goal is activation or silencing of cytotoxic T cells, it has become clear that the primary
target should be the APC, not the T cell itself.
5. NPs for Chronic Non-Communicable Diseases
The immune system has evolved several checkpoints to avoid self-recognition and auto-immunity.
This is an important feature of the immune system and it is key to balance the capacity to recognize
and clear infections. Several diseases, however, such as Parkinson′s and Alzheimer′s diseases,
are related to the aggregation of self-proteins, and a large number of chronic diseases, such as
rheumatoid arthritis and psoriasis, are caused by the excessive production of inflammatory cytokines.
The immune system is often unable to tackle these diseases as it has learned not to respond to the “self”.
NPs, however, are capable of bypassing tolerance against self-proteins by adding a viral fingerprint
to those proteins [88]. This finding opened new possibilities to employ NPs not only as vaccines
against infectious diseases but also against chronic and auto-immune diseases. For psoriasis, it is
now well established that interleukin IL-17 is involved in the formation of the skin lesions, a notion
Vaccines 2017, 5, 6 10 of 15
recently confirmed in humans by the success of monoclonal antibodies against IL-17A or the receptor
IL-17RA in controlling and reversing the skin disease [89]. These treatments are now on the market or
in phase III trials with great safety profiles and they are highly efficacious [90]. Although successful,
employing monoclonal antibodies against chronic diseases can be a costly endeavor, and vaccination
stands as a more cost-effective alternative. It has been shown that a vaccine employing a VLP coupled
to IL-17 was capable of ameliorating the symptoms of auto-immune disease models of encephalitis
and arthritis [15].
Another example of vaccines targeting self-antigens is the CAD106 vaccine against Alzheimer′s.
The rationale behind this vaccine is to induce antibodies against the self-protein Aβ implicated in the
pathology of Alzheimer’s. The vaccine has reached phase III now, with acceptable safety levels and a
confirmed capacity to induce long-lasting antibodies [17].
6. Use of NPs as Anti-Viral and Delivery Systems
Due to the diversity of materials from which NPs can be built, different particles can be employed
in a range of applications that are not limited to the field of vaccines.
The use of NPs has been reported with functionalized surfaces to harbor anti-viral properties, by
interacting with the hydrophobic regions of the envelope of the HIV virus and reducing the capacity
of the infection of the virus. The treatment was able to reduce the transduction ability of viruses in
50% [91]. Although rather preliminary, this study provides a new range of application for NPs.
A promising field that also relates to vaccines is using NPs as a cargo of immunogens that can
modulate the immune system. The advantages of packing TLR ligands inside VLPs and other NPs,
as mentioned earlier, are already well established, and the response generated against heterologous
antigens coupled to VLPs with CpG is remarkably stronger in terms of the expansion of specific
CD8+ T cells and the production of cytokines [68,70]. Along the same lines, different groups have
been attempting to pack other immune modulators, such as small interference RNA (siRNA), in
addition to functionalization of the surface of the particles which allows the targeted delivery of
siRNA to specific cell types [57]. Studies in mice employing the concomitant use of CpG and siRNA
encapsulated by liposomes targeting the anti-inflammatory cytokine IL-10 in a vaccine regime against
B cell lymphoma [92] and melanoma [93] demonstrated the ability to modulate the Th1:Th2 balance in
order to improve anti-tumor immunity.
Beside the promising results so far, this system stands as an interesting platform since it is able to
modulate cytokine production without any long-lasting effects. This is not only important for clinical
applications, but it will very likely provide an important tool for further understanding the intricate
dynamics of cytokines and the immune system.
7. Final Remarks
The use of NPs for vaccine development holds enormous promise not only for the vaccine field
but also as a valuable tool to study the ins and outs of the immune system. To observe and learn
how the immune system of vertebrates, especially mammals, evolves in response to viruses and other
pathogens can provide valuable clues that will enable researchers to rationally manipulate the immune
response and tailor better vaccines. The growing number of NPs with different immunomodulatory
and adjuvant characteristics will provide the tools necessary to develop more efficient vaccines,
both prophylactic and therapeutic, aiming to tackle infectious, autoimmune and chronic diseases.
Currently, great efforts are being made towards understanding and modulating the immune
response raised by NPs. To this end, basic and clinical research shall elucidate the mechanisms and the
optimal combinations and regimens to better mimic pathogens and to induce protective responses
and memory.
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